메뉴 건너뛰기




Volumn 33, Issue 32, 2015, Pages 3727-3732

Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; REGORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

EID: 84941331409     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.9569     Document Type: Article
Times cited : (80)

References (59)
  • 2
    • 79251470391 scopus 로고    scopus 로고
    • Projections of the cost of cancer care in the United States: 2010-2020
    • Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
    • (2011) J Natl Cancer Inst , vol.103 , pp. 117-128
    • Mariotto, A.B.1    Yabroff, K.R.2    Shao, Y.3
  • 3
    • 79954499886 scopus 로고    scopus 로고
    • Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    • Wilhelm SM, Dumas J, Adnane L, et al: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255, 2011
    • (2011) Int J Cancer , vol.129 , pp. 245-255
    • Wilhelm, S.M.1    Dumas, J.2    Adnane, L.3
  • 4
    • 84872921660 scopus 로고    scopus 로고
    • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial
    • Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
    • (2013) Lancet , vol.381 , pp. 303-312
    • Grothey, A.1    Van Cutsem, E.2    Sobrero, A.3
  • 5
    • 33745972934 scopus 로고    scopus 로고
    • ∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    • ∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 3061-3068
    • Toffoli, G.1    Cecchin, E.2    Corona, G.3
  • 6
    • 80053610056 scopus 로고    scopus 로고
    • Improved curve fits to summary survival data: Application to economic evaluation of health technologies
    • Hoyle MW, Henley W: Improved curve fits to summary survival data: Application to economic evaluation of health technologies. BMC Med Res Methodol 11:139, 2011
    • (2011) BMC Med Res Methodol , vol.11 , pp. 139
    • Hoyle, M.W.1    Henley, W.2
  • 8
    • 0034922729 scopus 로고    scopus 로고
    • EQ-5D: A measure of health status from the EuroQol group
    • Rabin R, de Charro F: EQ-5D: A measure of health status from the EuroQol group. Ann Med 33:337-343, 2001
    • (2001) Ann Med , vol.33 , pp. 337-343
    • Rabin, R.1    De Charro, F.2
  • 9
    • 33748558111 scopus 로고    scopus 로고
    • Health state utilities for metastatic breast cancer
    • Lloyd A, Nafees B, Narewska J, et al: Health state utilities for metastatic breast cancer. Br J Cancer 95:683-690, 2006
    • (2006) Br J Cancer , vol.95 , pp. 683-690
    • Lloyd, A.1    Nafees, B.2    Narewska, J.3
  • 11
    • 84901937880 scopus 로고    scopus 로고
    • Optimizing treatment outcomes with regorafenib Personalized dosing and other strategies to support patient care
    • Grothey A, George S, van Cutsem E, et al Optimizing treatment outcomes with regorafenib Personalized dosing and other strategies to support patient care. Oncologist 19:669-680, 2014
    • (2014) Oncologist , vol.19 , pp. 669-680
    • Grothey, A.1    George, S.2    Van Cutsem, E.3
  • 13
    • 17544362070 scopus 로고    scopus 로고
    • Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis
    • Tumeh JW, Moore SG, Shapiro R, et al: Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 5:153-162, 2005
    • (2005) Expert Rev Pharmacoecon Outcomes Res , vol.5 , pp. 153-162
    • Tumeh, J.W.1    Moore, S.G.2    Shapiro, R.3
  • 14
    • 80052761895 scopus 로고    scopus 로고
    • A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer
    • Goulart B, Ramsey S: A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14:836-845, 2011
    • (2011) Value Health , vol.14 , pp. 836-845
    • Goulart, B.1    Ramsey, S.2
  • 15
    • 84927615521 scopus 로고    scopus 로고
    • First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis
    • Goldstein DA, Chen Q, Ayer T, et al: First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis. J Clin Oncol 33:1112-1118, 2015
    • (2015) J Clin Oncol , vol.33 , pp. 1112-1118
    • Goldstein, D.A.1    Chen, Q.2    Ayer, T.3
  • 16
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    • Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Díaz-Rubio, E.3
  • 17
    • 49049105525 scopus 로고    scopus 로고
    • Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study
    • Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 26:3523-3529, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 3523-3529
    • Hochster, H.S.1    Hart, L.L.2    Ramanathan, R.K.3
  • 18
    • 84871720057 scopus 로고    scopus 로고
    • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial
    • Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
    • (2013) Lancet Oncol , vol.14 , pp. 29-37
    • Bennouna, J.1    Sastre, J.2    Arnold, D.3
  • 19
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 20
    • 84902247358 scopus 로고    scopus 로고
    • Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC)
    • LBA388
    • Koopman M, Simkens L, May A, et al: Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl 3; abstr LBA388)
    • (2014) J Clin Oncol , vol.32
    • Koopman, M.1    Simkens, L.2    May, A.3
  • 21
    • 84867047384 scopus 로고    scopus 로고
    • Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    • Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 3499-3506
    • Van Cutsem, E.1    Tabernero, J.2    Lakomy, R.3
  • 22
    • 84930437602 scopus 로고    scopus 로고
    • RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp)
    • 512
    • Tabernero J, Cohn AL, Obermannova R, et al: RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 33, 2015 (suppl 3; abstr 512)
    • (2015) J Clin Oncol , vol.33
    • Tabernero, J.1    Cohn, A.L.2    Obermannova, R.3
  • 23
    • 63849088630 scopus 로고    scopus 로고
    • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    • Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
    • (2009) N Engl J Med , vol.360 , pp. 1408-1417
    • Van Cutsem, E.1    Köhne, C.H.2    Hitre, E.3
  • 24
    • 79956298812 scopus 로고    scopus 로고
    • Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    • Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 2011-2019
    • Van Cutsem, E.1    Köhne, C.H.2    Láng, I.3
  • 25
    • 79956310674 scopus 로고    scopus 로고
    • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
    • Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546, 2011
    • (2011) Ann Oncol , vol.22 , pp. 1535-1546
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3
  • 26
    • 78049341541 scopus 로고    scopus 로고
    • Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    • De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
    • (2010) JAMA , vol.304 , pp. 1812-1820
    • De Roock, W.1    Jonker, D.J.2    Di Nicolantonio, F.3
  • 27
    • 84875742535 scopus 로고    scopus 로고
    • Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab
    • Peeters M, Douillard JY, Van Cutsem E, et al: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31:759-765, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 759-765
    • Peeters, M.1    Douillard, J.Y.2    Van Cutsem, E.3
  • 28
    • 78149250536 scopus 로고    scopus 로고
    • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
    • Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 4697-4705
    • Douillard, J.Y.1    Siena, S.2    Cassidy, J.3
  • 29
    • 84883680951 scopus 로고    scopus 로고
    • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    • Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
    • (2013) N Engl J Med , vol.369 , pp. 1023-1034
    • Douillard, J.Y.1    Oliner, K.S.2    Siena, S.3
  • 30
    • 84905870196 scopus 로고    scopus 로고
    • PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer
    • Schwartzberg LS, Rivera F, Karthaus M, et al: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240-2247, 2014
    • (2014) J Clin Oncol , vol.32 , pp. 2240-2247
    • Schwartzberg, L.S.1    Rivera, F.2    Karthaus, M.3
  • 31
    • 84879786289 scopus 로고    scopus 로고
    • Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracilresistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial
    • Seymour MT, Brown SR, Middleton G, et al: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracilresistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. Lancet Oncol 14:749-759, 2013
    • (2013) Lancet Oncol , vol.14 , pp. 749-759
    • Seymour, M.T.1    Brown, S.R.2    Middleton, G.3
  • 32
    • 84908573757 scopus 로고    scopus 로고
    • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
    • Heinemann V, von Weikersthal LF, Decker T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 15:1065-1075, 2014
    • (2014) Lancet Oncol , vol.15 , pp. 1065-1075
    • Heinemann, V.1    Von Weikersthal, L.F.2    Decker, T.3
  • 34
    • 84927641527 scopus 로고    scopus 로고
    • Can money really be no object when cancer care is the subject?
    • Saltz LB: Can money really be no object when cancer care is the subject? J Clin Oncol 3:1093-1094, 2015
    • (2015) J Clin Oncol , vol.3 , pp. 1093-1094
    • Saltz, L.B.1
  • 35
    • 84938292355 scopus 로고    scopus 로고
    • The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: A critique of the evidence
    • Wade R, Duarte A, Simmonds M, et al: The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: A critique of the evidence. Pharmacoeconomics 33:457-466, 2015
    • (2015) Pharmacoeconomics , vol.33 , pp. 457-466
    • Wade, R.1    Duarte, A.2    Simmonds, M.3
  • 36
    • 33846477195 scopus 로고    scopus 로고
    • Costeffectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
    • Starling N, Tilden D, White J, et al: Costeffectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 96:206-212, 2007
    • (2007) Br J Cancer , vol.96 , pp. 206-212
    • Starling, N.1    Tilden, D.2    White, J.3
  • 37
    • 79551512524 scopus 로고    scopus 로고
    • Costeffectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer
    • Shiroiwa T, Motoo Y, Tsutani K: Costeffectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 14:375-384, 2010
    • (2010) Mol Diagn Ther , vol.14 , pp. 375-384
    • Shiroiwa, T.1    Motoo, Y.2    Tsutani, K.3
  • 38
    • 69949157429 scopus 로고    scopus 로고
    • Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial
    • Mittmann N, Au HJ, Tu D, et al: Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 101:1182-1192, 2009
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1182-1192
    • Mittmann, N.1    Au, H.J.2    Tu, D.3
  • 39
    • 80053475784 scopus 로고    scopus 로고
    • KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective
    • Blank PR, Moch H, Szucs TD, et al: KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 17:6338-6346, 2011
    • (2011) Clin Cancer Res , vol.17 , pp. 6338-6346
    • Blank, P.R.1    Moch, H.2    Szucs, T.D.3
  • 40
    • 84870878845 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
    • Behl AS, Goddard KA, Flottemesch TJ, et al: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 104:1785-1795, 2012
    • (2012) J Natl Cancer Inst , vol.104 , pp. 1785-1795
    • Behl, A.S.1    Goddard, K.A.2    Flottemesch, T.J.3
  • 41
    • 39049148881 scopus 로고    scopus 로고
    • Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan: A Belgian analysis
    • Annemans L, Van Cutsem E, Humblet Y, et al: Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan: A Belgian analysis. Acta Clin Belg 62:419-425, 2007
    • (2007) Acta Clin Belg , vol.62 , pp. 419-425
    • Annemans, L.1    Van Cutsem, E.2    Humblet, Y.3
  • 42
    • 33751178148 scopus 로고    scopus 로고
    • Cetuximab in the treatment of metastatic colorectal cancer: A model-based costeffectiveness analysis
    • Norum J: Cetuximab in the treatment of metastatic colorectal cancer: A model-based costeffectiveness analysis. J Chemother 18:532-537, 2006
    • (2006) J Chemother , vol.18 , pp. 532-537
    • Norum, J.1
  • 43
    • 84861631258 scopus 로고    scopus 로고
    • Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
    • Vijayaraghavan A, Efrusy MB, Göke B, et al: Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 131:438-445, 2012
    • (2012) Int J Cancer , vol.131 , pp. 438-445
    • Vijayaraghavan, A.1    Efrusy, M.B.2    Göke, B.3
  • 44
    • 84891634642 scopus 로고    scopus 로고
    • A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer
    • Lange A, Prenzler A, Frank M, et al: A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer 50:40-49, 2014
    • (2014) Eur J Cancer , vol.50 , pp. 40-49
    • Lange, A.1    Prenzler, A.2    Frank, M.3
  • 45
    • 84882958463 scopus 로고    scopus 로고
    • Economic studies in colorectal cancer: Challenges in measuring and comparing costs
    • Yabroff KR, Borowski L, Lipscomb J: Economic studies in colorectal cancer: Challenges in measuring and comparing costs. J Natl Cancer Inst Monogr 2013:62-78, 2013
    • (2013) J Natl Cancer Inst Monogr , vol.2013 , pp. 62-78
    • Yabroff, K.R.1    Borowski, L.2    Lipscomb, J.3
  • 46
    • 0036738342 scopus 로고    scopus 로고
    • Health economic evaluations: The special case of end-stage renal disease treatment
    • Winkelmayer WC, Weinstein MC, Mittleman MA, et al: Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 22:417-430, 2002
    • (2002) Med Decis Making , vol.22 , pp. 417-430
    • Winkelmayer, W.C.1    Weinstein, M.C.2    Mittleman, M.A.3
  • 47
    • 58849090571 scopus 로고    scopus 로고
    • An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard
    • Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 12:80-87, 2009
    • (2009) Value Health , vol.12 , pp. 80-87
    • Lee, C.P.1    Chertow, G.M.2    Zenios, S.A.3
  • 48
    • 84907360483 scopus 로고    scopus 로고
    • Updating cost-effectiveness: The curious resilience of the $50, 000-per-QALY threshold
    • Neumann PJ, Cohen JT, Weinstein MC: Updating cost-effectiveness: The curious resilience of the $50, 000-per-QALY threshold. N Engl J Med 371:796-797, 2014
    • (2014) N Engl J Med , vol.371 , pp. 796-797
    • Neumann, P.J.1    Cohen, J.T.2    Weinstein, M.C.3
  • 49
    • 0033914269 scopus 로고    scopus 로고
    • Willingness to pay for a quality-adjusted life year: In search of a standard
    • Hirth RA, Chernew ME, Miller E, et al: Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 20:332-342, 2000
    • (2000) Med Decis Making , vol.20 , pp. 332-342
    • Hirth, R.A.1    Chernew, M.E.2    Miller, E.3
  • 50
    • 84875467293 scopus 로고    scopus 로고
    • Consolidated Health Economic Evaluation Reporting Standards (CHEERS): Explanation and elaboration-A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
    • Husereau D, Drummond M, Petrou S, et al: Consolidated Health Economic Evaluation Reporting Standards (CHEERS): Explanation and elaboration-A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16:231-250, 2013
    • (2013) Value Health , vol.16 , pp. 231-250
    • Husereau, D.1    Drummond, M.2    Petrou, S.3
  • 51
    • 77958528027 scopus 로고    scopus 로고
    • What is the price benchmark to replace average wholesale price (AWP) ?
    • Curtiss FR, Lettrich P, Fairman KA: What is the price benchmark to replace average wholesale price (AWP) ? J Manag Care Pharm 16:492-501, 2010
    • (2010) J Manag Care Pharm , vol.16 , pp. 492-501
    • Curtiss, F.R.1    Lettrich, P.2    Fairman, K.A.3
  • 52
    • 59749092456 scopus 로고    scopus 로고
    • Limits on Medicare's ability to control rising spending on cancer drugs
    • Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
    • (2009) N Engl J Med , vol.360 , pp. 626-633
    • Bach, P.B.1
  • 53
    • 84924620555 scopus 로고    scopus 로고
    • Convergence of decision rules for value-based pricing of new innovative drugs
    • Gandjour A: Convergence of decision rules for value-based pricing of new innovative drugs. Expert Rev Pharmacoecon Outcomes Res 15:209-213, 2015
    • (2015) Expert Rev Pharmacoecon Outcomes Res , vol.15 , pp. 209-213
    • Gandjour, A.1
  • 54
    • 84922219447 scopus 로고    scopus 로고
    • Value-based differential pricing: Efficient prices for drugs in a global context
    • Danzon P, Towse A, Mestre-Ferrandiz J: Value-based differential pricing: Efficient prices for drugs in a global context. Health Econ 24:294-301, 2015
    • (2015) Health Econ , vol.24 , pp. 294-301
    • Danzon, P.1    Towse, A.2    Mestre-Ferrandiz, J.3
  • 55
    • 84880275207 scopus 로고    scopus 로고
    • Reforming the payment system for medical oncology
    • Bach PB: Reforming the payment system for medical oncology. JAMA 310:261-262, 2013
    • (2013) JAMA , vol.310 , pp. 261-262
    • Bach, P.B.1
  • 56
    • 84908150068 scopus 로고    scopus 로고
    • Indication-specific pricing for cancer drugs
    • Bach PB: Indication-specific pricing for cancer drugs. JAMA 312:1629-1630, 2014
    • (2014) JAMA , vol.312 , pp. 1629-1630
    • Bach, P.B.1
  • 57
    • 77949529722 scopus 로고    scopus 로고
    • Cancer's next frontier: Addressing high and increasing costs
    • Elkin EB, Bach PB: Cancer's next frontier: Addressing high and increasing costs. JAMA 303:1086-1087, 2010
    • (2010) JAMA , vol.303 , pp. 1086-1087
    • Elkin, E.B.1    Bach, P.B.2
  • 58
    • 35348976024 scopus 로고    scopus 로고
    • Satisfaction guaranteed: "Payment by results" for biologic agents
    • Garber AM, McClellan MB: Satisfaction guaranteed: "Payment by results" for biologic agents. N Engl J Med 357:1575-1577, 2007
    • (2007) N Engl J Med , vol.357 , pp. 1575-1577
    • Garber, A.M.1    McClellan, M.B.2
  • 59
    • 84919473012 scopus 로고    scopus 로고
    • Lowering medical costs through the sharing of savings by physicians and patients: Inclusive shared savings
    • Schmidt H, Emanuel EJ: Lowering medical costs through the sharing of savings by physicians and patients: Inclusive shared savings. JAMA Intern Med 174:2009-2013, 2014
    • (2014) JAMA Intern Med , vol.174 , pp. 2009-2013
    • Schmidt, H.1    Emanuel, E.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.